Eif2B2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | eIF2B2 (Eukaryotic Translation Initiation Factor 2B Subunit Beta) |
|---|---|
| Gene | EIF2B2 |
| UniProt ID | P49407 |
| PDB Structure | 6O9Y, 6O9Z |
| Molecular Weight | 39 kDa |
| Subcellular Localization | Cytoplasm |
| Protein Family | eIF2B family |
eIF2B2 is the beta subunit of the eukaryotic translation initiation factor 2B complex. The eIF2B heterodecamer consists of two copies each of five subunits (alpha, beta, gamma, delta, epsilon). The beta subunit contributes to the structural organization and stability of the complex. The subunits form a symmetrical decamer with regulatory subunits (alpha, beta) forming the core and catalytic subunits (epsilon) at the periphery[1].
The eIF2B complex functions as the guanine nucleotide exchange factor (GEF) for eIF2, catalyzing the exchange of GDP for GTP. This reaction regenerates active eIF2-GTP, which is essential for the formation of the ternary complex required for translation initiation[2].
In the normal nervous system, eIF2B2 plays a critical role in regulating protein synthesis in neurons and glial cells. The eIF2B complex is a central regulator of the integrated stress response (ISR), where phosphorylation of eIF2alpha at Ser51 inhibits eIF2B activity, leading to translational attenuation while selectively promoting expression of stress-response genes. This allows cells to conserve resources and focus on stress adaptation[3].
In oligodendrocytes, eIF2B function is essential for myelin production and maintenance. The stress-responsive regulation through eIF2B helps glial cells cope with the high metabolic demands of myelination.
Mutations in EIF2B2 are a common cause of vanishing white matter disease (VWM), an autosomal recessive leukodystrophy. Pathogenic variants reduce eIF2B activity, compromising the integrated stress response in oligodendrocytes and astrocytes. This leads to progressive white matter degeneration with cystic changes. The disease is characterized by cerebellar ataxia, spasticity, and cognitive decline[4].
The pathophysiology involves impaired stress response in glial cells, making them vulnerable to various cellular stresses. Episodes of deterioration are often triggered by minor infections or head trauma.
Therapeutic approaches for VWM associated with EIF2B2 mutations include:
ISRIB (Integrated Stress Response Inhibitor): A small molecule that stabilizes eIF2B and restores function despite eIF2alpha phosphorylation. Shows promise in preclinical models[5].
Pharmacological chaperones: Small molecules that can stabilize mutant eIF2B complexes and enhance activity.
Gene therapy: Viral delivery of wild-type EIF2B2 to restore normal function.
The study of Eif2B2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.